Safety and Effectiveness of Thrombolytic Therapy Compared with Standard Anticoagulation in Subjects with Submassive Pulmonary Embolism

Objective: Thrombolytic and anticoagulation therapy modalities are the possible treatment for submassive pulmonary embolism (PE). However, the indications are still the subject of debate. The aim of the present study was to compare the efficacies of thrombolytic and standard anticoagulation treatment modalities on mortality and also to determine the safety of thrombolytic treatment in subjects with submassive PE. Materials and Methods: Subjects with submassive PE were recruited from the intensive care unit (ICU). Demographic data, comorbidity, bedside echocardiography (ECHO) findings, treatment procedure, treatment-related side effects, and total length of stay in the hospital and ICU were collected. Control ECHO was performed 48 h after the initiation of treatment. Short-term and 1-year mortality rates were recorded. The correlation between the increased risk for major bleeding and thrombolytic treatment was assessed. Results: A total of 54 subjects were enrolled during the study period. The median age of the subjects was 66 (54–73) years. Of the 54 subjects, 18 (33.3%) underwent thrombolytic treatment, and 36 (66.7%) received standard anticoagulation therapy. Short-term and 1-year mortality rates were statistically lower in subjects who received thrombolytic therapy (p=0.02 and p=0.04, respectively). The reduction in mean pulmonary arterial pressure was significantly higher in the thrombolytic treatment group (p

Kaynakça

Konstantinides SV, Barco S, Lankeit M, Meyer G. Management of Pulmonary Embolism: An Update. J Am Coll Cardiol 2016;67(8):976–90.

Sekhri V, Mehta N, Rawat N, Lehrman SG, Aronow WS. Management of massive and nonmassive pulmonary embolism. Arch Med Sci 2012;8(6):957–69. [CrossRef]

Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, et al. 2014 ESC guidelines on the diagnosis and management of acutepulmonary embolism. Eur Heart J 2014;35(43):3033–69.

Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and ExpertPanel Report. Chest 2016;149(2):315–52. [CrossRef]

Grifoni S, Olivotto I, Cecchini P, Pieralli F, Camaiti A, Santoro G, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000;101(24):2817–22. [CrossRef]

Todd JL, Tapson VF. Thrombolytic therapy for acute pulmonary embolism: a critical appraisal. Chest 2009;135(5):1321–9. [CrossRef]

Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004;110(6):744–9. [CrossRef]

Dalen JE. The uncertain role of thrombolytic therapy in the treatment of pulmonary embolism. Arch Intern Med 2002;162(22):2521–3.

Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, et al. Management of massive and submassive pulmonary embolism, iliofemoraldeep vein thrombosis, and chronic thromboem- bolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011;123(16):1788–830. [CrossRef]

Heit JA, Melton LJ 3rd, Lohse CM, Petterson TM, Silverstein MD, Mohr DN,et al. Incidence of venous thromboembolism in hospitalized patients vscommunity residents. Mayo Clin Proc 2001;76(11):1102– 10. [CrossRef]

Sanchez O, Planquette B, Meyer G. Update on acute pulmonary embolism. Eur Respir Rev 2009;18(113):137–47. [CrossRef]

Ryan MG, Westrich GH, Potter HG, Sharrock N, Maun LM, Macaulay W, et al. Effect of mechanical compression on the prevalence of proximal deep venous thrombosis as assessed by magnetic resonance venography. J Bone Joint Surg Am 2002;84-A(11):1998–2004. [CrossRef]

Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, et al. Guidelines on the diagnosis and management of acute pulmonaryembolism: the Task Force for the Diagnosis and Management of AcutePulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008;29(18):2276–315.

Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest PhysiciansEvidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S–e496S. [CrossRef]

Fei J, Tang Y, Wu J, Kang L, Zhao J, Dai H, et al. Thrombolytic and anticoagulant therapy for acute submassive pulmonary embolism. Exp Ther Med 2014;7(1):103–8. [CrossRef]

Berghaus TM, Thilo C, Bluethgen A, von Scheidt W, Schwaiblmair M. Effectiveness of thrombolysis in patients with intermediate-risk pulmonary embolism: influence on length of hospital stay. Adv Ther 2010;27(9):648–54. [CrossRef]

Tapson VF, Carroll BA, Davidson BL, Elliott CG, Fedullo PF, Hales CA, et al. The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. Am J Respir Crit Care Med 1999;160(3):1043–66. [CrossRef]

American College of Emergency Physicians Clinical Policies Committee; Clinical Policies Committee Subcommittee on Suspected Pulmonary Embolism. Clinical policy: critical issues in the evaluation and management of adultpatients presenting with suspected pulmonary embolism. Ann Emerg Med 2003;41(2):257–70. [CrossRef]

Meneveau N, Ming LP, Séronde MF, Mersin N, Schiele F, Caulfield F, et al. In-hospital and long-term outcome after sub-massive and massivepulmonary embolism submitted to thrombolytic therapy. Eur Heart J 2003;24(15):1447–54. [CrossRef]

Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the InternationalCooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353(9162):1386–9. [CrossRef]

Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser K, Rauber K, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: resultsof a multicenter registry. Circulation 1997;96(3):882– 8. [CrossRef]

Lozier JN, Elinoff JM, Suffredini AF, Rosing DR, Sidenko S, Sherry RM, et al. Low-dose, short course alteplase treatment of submassive pulmonaryembolism: a case series from the National Institutes of Health ClinicalCenter. Blood Coagul Fibrinolysis 2018;29(8):701–7.

Jimenez D, Martin-Saborido C, Muriel A, Zamora J, Morillo R, Barrios D, et al. Efficacy and safety outcomes of recanalisation procedures in patients with acute symptomatic pulmonary embolism: systematic review and network meta-analysis. Thorax 2018;73(5):464–71. [CrossRef]

Perlroth DJ, Sanders GD, Gould MK. Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. Arch Intern Med 2007;167(1):74–80. [CrossRef]

Zamanian RT, Gould MK. Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism. Curr Opin Pulm Med 2008;14(5):422–6. [CrossRef]

Ramakrishnan N. Thrombolysis is not warranted in submassive pulmonary embolism: a systematic review and meta-analysis. Crit Care Resusc 2007;9(4):357–63.

Liew J, Stevens J, Slatore C. Refractory Hypoxemia in a Patient with Submassive Pulmonary Embolismand an Intracardiac Shunt: A Case Report and Review of the Literature. Perm J 2018;22:17–061.

Fiumara K, Kucher N, Fanikos J, Goldhaber SZ. Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol 2006;97(1):127–9. [CrossRef]

Cao Y, Zhao H, Gao W, Wang Y, Cao J. Systematic review and metaanalysis for thrombolysis treatment in patients with acute submassive pulmonary embolism. Patient Prefer Adherence 2014;8:275–82. [CrossRef]

Nakamura S, Takano H, Kubota Y, Asai K, Shimizu W. Impact of the efficacy of thrombolytic therapy on the mortality of patientswith acute submassive pulmonary embolism: a meta-analysis. J Thromb Haemost 2014;12(7):1086–95. [CrossRef]

Geibel A, Olschewski M, Zehender M, Wilsch M, Odening K, Heinrich F, et al. Possible gender-related differences in the risk-to-benefit ratio of thrombolysis for acute submassive pulmonary embolism. Am J Cardiol 2007;99(1):103–7. [CrossRef]

Engelberger RP, Kucher N. Reperfusion Treatment for Acute Pulmonary Embolism. Hamostaseologie 2018;38(2):98–105. [CrossRef]

Kaynak Göster

  • ISSN: 2149-2247
  • Yayın Aralığı: Yılda 6 Sayı
  • Başlangıç: 2002
  • Yayıncı: Kare Yayıncılık

4.3b3.6b